Transcatheter arterial embolization (TAB) and transcatheter arterial infusion (TAI) using cisplatin suspended in Lipiodol® Ultra-Fluide (Cisplatin/Lipiodol) are considered to be useful tumor-targeting therapies for hepatocellular carcinoma. However, little information is available on adverse events due to injection of Cisplatin/Lipiodol because the combined use Lipiodol and Cisplatin has not been approved by the Japanese government yet. Upon investigating the frequency and time of onset of adverse events following injection of Cisplatin/Lipiodol in 16 in-patients at Mie University Hospital, the frequency of the subjective symptoms of stomachache including epigastrium ache (75.0%), nausea or vomiting (50.0%), fever (50.0%), and gastric region discomfort (37.5%) was observed to be high. Further, leucocytes and neutrophils increased 2 days after injection (p< 0.001) and the onset of thrombocytopenia was much earlier than that following injection of Cisplatin alone. Severe adverse events defined as grade 3 or 4 in the Common Toxicity Criteria for Adverse Events Version 3.0 (JCOG/JSCO version, National Cancer Institute) were observed in 12 patients. These results suggest that great caution should be exercised with respect to adverse events occurring during Cisplatin/Lipiodol therapy.
雑誌名
医療薬学
巻
34
号
8
ページ
794 - 799
発行年
2008-08-10
ISSN
1346-342X
書誌レコードID
AA11527197
フォーマット
application/pdf
著者版フラグ
publisher
その他のタイトル
Adverse Events due to Cisplatin-Lipiodol® Ultra-Fluide Suspension in Patients with Primary Hepatocellular Carcinoma
原発性肝がんに対するシスプラチン・リピオドール療法時の有害事象調査
39A16148.pdf
(88.18KB)
